The only interesting recent bit of news, to me, came from the update of the ovarian cancer trial in March. The company amended the trial from two treatments to four, which to me means that people are surviving and the treatment is working.
Ovarian cancer doesn't have a long survival time. It's like pancreatic cancer, once it's found it usually has spread to other parts of the body. So for AVXT to be doubling the amount of treatments is bullish news.
The autologous vaccine technology has already been validated with the approval of Dendreon's Provenge. It is also looking good for Northwest Biotherapeutics, where patients being treated with the same kind of vaccine for brain cancer are living longer.
And of course, AVXT's trial for the autologous vaccine against melanoma produced way better results than the currently approved medicines.
News 
Market Data 
Discover 
